0 P rocedures for controlling the storage of product in storage areas and stock rooms were not implemented to prevent mix-ups, damage, other adverse effects .
Inspection Record
Bausch and Lomb, Inc — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The design plan does not describe the design and development activities, define responsibilities for implementation of design and development activities, and identify and describe the interfaces with other groups or activities as appropriate.
Specifically, The current analytical test methods for OTC drug products are not stability-indicating to demonstrate levels of degradation or other impurities that may exist in such products .
A correction or removal, co nducted to reduce a risk to health posed by a device, was not reported in writing to FDA.
There are no written procedures for production and process controls designed to ensure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess .
An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a market dev ice may have cause or contributed to a death or serious injury.
Appropriate procedures have not been defined and documented for controlling environmental conditions.
Employees are not given training in the particular operations they perf orm as part of their function.
Procedures have not been documented to prevent contaminations of equipment or product by certain substances.
Quality audits were not c onducted to verify that the quality system is effective in fulfilling your quality system objectives.
A validated process was not revalidated when changes or process deviations occurred.
Complaints involving the possible failure of a device to meet any of its specifications were not investigated where necessary .
Written procedures are not follo wed for the cleaning and maint enance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product .
Proce dures have not been followed to prevent contamination of equipment or product by certain substances.
2 Procedure s have not been implemented to ensure that mix-ups, damage, or other adverse effects to product do not occur during handling .
Design reviews wer e not p erformed at ap propriate times, following the review schedule.
Procedures for controlling the storage of product in s torage areas and stock rooms were not established to prevent mix-ups, damage, other adverse effects.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Invacare Corporation2015-07-11 · US FDASimilar to finding 6 An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have…
- BPI Labs, LLC2026-04-17 · US FDASimilar to finding 13 Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing…
- Eugia Pharma Specialities Limited2026-02-06 · US FDASimilar to finding 8 Employees are not given training in the particular operations they perform as part of their function.
- Denver Solutions LLC dba Leiters Health2024-04-05 · US FDASimilar to finding 13 Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding…
- Fresenius Kabi Oncology Limited2023-10-10 · US FDASimilar to finding 13 Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or…
A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.